Bladder tissue study for early-stage bladder cancer
Part of Cancer, Kidney & urinary clinical trials.
This study looks at how the bladder reacts to a standard treatment called BCG, which is given after surgery for early-stage bladder cancer. By checking the tissue and urine before treatment, the study aims to understand if the bladder is ready for BCG therapy, which could help improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have recently been diagnosed with a bladder lesion and undergone a TURBT surgery (a procedure to remove and examine bladder tissue) at Tata Memorial Centre.
- After the surgery, the pathology report must show non-muscle invasive bladder cancer (NMIBC), meaning the cancer has not spread into the deeper muscle layers of the bladder.
- You should not have any visible tumor remaining on your cystoscopy (a camera test) before starting the study treatment.
- You must not have a urinary tract infection before the cystoscopy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies a BCG-based bladder instillation in people with newly diagnosed, intermediate- or high-risk non-muscle invasive bladder cancer who have had their tumor fully removed. The goal is to see whether this treatment is safer and works better to lower the chance of the cancer coming back.
This study tries to predict whether BCG treatment will work for people with certain early-stage bladder cancers. It may help doctors better choose and monitor BCG for similar patients in the future.
This study tests a urine test that may help find bladder cancer early without needing invasive procedures. It is for people with high-grade or high-risk non-muscle-invasive bladder cancer who are receiving or have received BCG treatment.
This trial tests giving BCG immunotherapy at home instead of in the clinic, to reduce the burden of travel and hospital visits. It may help patients with non-muscle invasive bladder cancer who need BCG treatment after surgery.
This trial tests a new form of intravesical (given directly into the bladder) treatment called rMBCG for people with non-muscle invasive bladder cancer who have not had BCG therapy before. It may be an option for those with certain types of early bladder cancer, including carcinoma in situ (CIS) or papillary tumors after removal surgery.
This trial tests a personalized approach to using BCG immunotherapy for high-risk non-muscle-invasive bladder cancer. It aims to improve treatment response by tailoring the therapy based on your immune system.
Hear when a new Non-Invasive Bladder Urothelial Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.